FDA Warning Letters to Peptide Vendors: The Complete Tracker
A Living Record of FDA Enforcement Against Peptide Sellers
This FDA warning letter tracker records every letter the agency has issued to online peptide vendors, what each letter cited, and what happened next. It exists because no consolidated record does — the letters are scattered across FDA’s warning-letter index, and the pattern across them is more informative than any single letter. We update it when new letters are posted.
Warning letters are not findings of guilt. They are the agency’s formal notice that it believes a company is violating the Federal Food, Drug, and Cosmetic Act, with a 15-business-day window to respond. But taken together, the letters describe exactly what FDA’s Center for Drug Evaluation and Research looks for when it reviews a peptide vendor’s website — and that makes them the most useful compliance document the industry has.
The Tracker
| Letter date | Vendor | Products cited | Key theory | Status |
|---|---|---|---|---|
| Aug 24, 2026 | Peak Performance Peptides | GLP-1 class peptides, reconstitution water | Website claims establish intended human use; RUO disclaimer rejected | Posted Sep 1; response due ~Sep 15 |
| Aug 24, 2026 | Royal Peptides LLC | Semaglutide, tirzepatide, retatrutide, BAC water | BAC water marketed “alongside a peptide guide and peptide calculator” as evidence of intended use | Posted Sep 1 |
| Aug 24, 2026 | NuScience Peptides LLC | Semaglutide, tirzepatide, retatrutide, survodutide, mazdutide, BAC water | Reconstitution water sold beside injectables shows combined intended use | Posted Sep 1 |
| Aug 24, 2026 | Peptide Partners LLC | Semaglutide, tirzepatide, retatrutide, SS-31, tesamorelin, PT-141, reconstitution solution | Selling BAC water as solvent is “providing the means to prepare an injectable drug for human administration” | Posted Sep 1 (letter 735063) |
| Aug 24, 2026 | TXP Innovations LLC (Tex Peptides) | GLP-1 class, ipamorelin blends, BAC water | Claims on metabolic regulation, weight loss, cognitive function, sexual behavior cited as drug claims | Posted Sep 1 |
| Mar 31, 2026 | Seven vendors (batch) | Semaglutide, tirzepatide, BPC-157, others | BAC water itself concluded to be a drug when sold for reconstituting injectables | Posted Apr 2 |
| 2025 | USApeptide | Peptides, BAC water, insulin syringes | Syringes and BAC water sold alongside peptides as evidence of injection intent | Closed |
| Dec 2024 | Prime Peptides, Summit Research Peptides, Swisschems, Xcel Research | Semaglutide, tirzepatide | RUO-labeled but advertised for human use | Closed; Swiss Chems still operating |
Sources: FDA warning-letter index (Office of Unapproved Drugs and Labeling Compliance, CDER); letter numbers where published. Vendor product lists reflect what each letter named, not the vendor’s full catalog.
What the August 24 Letters Actually Say
The five August letters share a structure that reads like a template. Each opens by stating that FDA reviewed the vendor’s website in July 2026. Each identifies specific peptides sold on that site. Each quotes product descriptions, marketing copy, or educational content that FDA considers evidence of intended drug use under Section 201(g)(1) of the FD&C Act. And each concludes that the products are unapproved new drugs under Section 505(a) and misbranded under Section 502.
The critical move in every letter is the rejection of “research use only” labeling. FDA’s position is that a label does not determine intended use — the totality of the commercial presentation does. If a vendor’s website describes what a peptide does in the human body, sells the water needed to reconstitute it, links to a dosing calculator, and presents testimonials about results, then the “RUO” stamp on the vial is contradicted by everything around it (ArentFox Schiff analysis).
No products were tested. FDA did not claim any vial was underdosed, contaminated, or mislabeled as to contents. The entire case in each letter rests on website review — which means the enforcement risk is about marketing, not manufacturing.
The Bacteriostatic Water Theory
The most consequential development in the August letters is how FDA treats bacteriostatic water. This is not new — the March 31 batch had already concluded that BAC water sold for reconstituting peptides is itself a drug — but the August letters make the theory explicit and apply it more broadly.
The Peptide Partners letter states that selling reconstitution solution as a solvent is “providing the means to prepare an injectable drug for human administration.” The NuScience letter reasons that offering reconstitution water beside injectable products “demonstrates a combined intended use.” The Royal Peptides letter cites BAC water marketed “alongside a peptide guide and peptide calculator” as evidence (Sheppard Mullin analysis).
Under this reasoning, the water is not an unrelated accessory. A vendor that sells peptides, sells BAC water, and publishes reconstitution instructions has — in FDA’s view — assembled a kit for preparing an injectable drug, regardless of what the labels say. This theory reaches most of the research peptide market as it currently operates.
The Escalation Pattern
Reading the letters chronologically shows FDA’s theory expanding with each batch. The December 2024 letters focused on explicit therapeutic claims — vendors saying peptides treat obesity or improve health. By 2025, the agency was also citing clinical-trial summaries, social-media promotion, and product bundles. The March 2026 letters added the BAC water conclusion. The August 2026 letters combine all of these and extend the product list well beyond GLP-1s to SS-31, PT-141, tesamorelin, and growth-hormone secretagogue blends (Five Warning Letters and a Problem for the RUO Peptide Market).
Ten letters in twelve months, five on a single day, is a cadence that suggests systematic review rather than complaint-driven enforcement. The July website reviews that triggered the August letters were conducted in parallel across five companies, which points to a coordinated sweep.
What Happens After a Warning Letter
A warning letter gives the recipient 15 business days to respond with corrective actions. Most vendors respond by removing the cited claims, deleting reconstitution guides, and in some cases discontinuing named products. FDA then either closes the matter with a close-out letter or escalates.
Escalation options include seizure of products, injunction against continued sales, and — in cases the agency considers egregious — referral for criminal prosecution. The Paradigm Peptides case, in which the company’s founders pleaded guilty to federal charges in December 2025, and the June 2025 raid on Amino Asylum both followed periods of regulatory correspondence.
Of the four December 2024 recipients, Swiss Chems continues to operate. The others have either closed or substantially changed their catalogs. The August 2026 recipients’ responses were due in mid-September; as of this writing, none has publicly announced closure, and all five websites remain online with varying degrees of content removal.
What This Means for the Market
The letters establish that FDA’s enforcement priority is website content, not product quality. A vendor with excellent testing and honest COAs faces the same exposure as a vendor with none if both publish the same dosing guides and sell the same BAC water. Conversely, a vendor that strips therapeutic language, removes reconstitution instructions, and stops selling reconstitution supplies is — under the letters’ logic — substantially less exposed even if nothing about the products changed.
For researchers, the practical effect is that vendor websites are becoming less informative. Dosing guides, reconstitution calculators, and educational content about what compounds do are exactly what the letters cite. Vendors that respond to enforcement by removing this content will offer less guidance, and researchers will need to rely more on independent sources — including primary literature and sites like this one that do not sell the products they cover.
Frequently Asked Questions
Does an FDA warning letter mean a vendor’s products are unsafe?
No. The August 2026 letters were based entirely on website review. FDA did not test any product. A warning letter establishes that the agency believes the vendor’s marketing crosses into drug promotion — it says nothing about purity, contamination, or accuracy of contents.
Why does FDA treat bacteriostatic water as a drug?
Because it is sold for the purpose of reconstituting injectable peptides. FDA’s position, applied since the March 2026 letters, is that water marketed as a solvent for preparing injections is a drug component with the same intended use as the peptide it reconstitutes. Sold in isolation, BAC water is a sterile diluent; sold beside peptides with reconstitution instructions, it becomes part of an injection kit.
Can a vendor comply by adding “research use only” to every page?
No — that is the specific strategy the letters reject. FDA evaluates intended use from the totality of the website: product descriptions, educational content, supplies sold alongside, calculators, testimonials. A disclaimer contradicted by everything around it does not change the agency’s assessment.
How many peptide vendors have received FDA warning letters?
At least ten in the twelve months to September 2026: four in December 2024, one or more in 2025, seven in March 2026, and five on August 24, 2026. The index is public at fda.gov under warning letters, filtered by CDER’s Office of Unapproved Drugs and Labeling Compliance.
PeptideQuill covers the research peptide industry. This tracker is updated as new letters are posted. Last updated September 24, 2026. This content is for informational purposes and does not constitute legal advice.
